CLAIMS

1. A compound of formula (I), a stereoisomer or a tautomer thereof or a pharmaceutically acceptable salt thereof,



(I)

wherein,

the carbon atom with "*" may be a chiral carbon atom present in a form of a single (*R*) or (*S*) enantiomer or in a form enriched with one enantiomer;

X is selected from the group consisting of N and CH;

R_1 is selected from the group consisting of H, F, Cl, Br, I, CN, C_{1-6} alkyl, C_{3-6} cycloalkyl, $-N(R_a)(R_b)$ and $-O(R_c)$, the C_{1-6} alkyl and C_{3-6} cycloalkyl being optionally substituted with 1, 2 or 3 R_d;

R_2 is C_{1-6} alkyl, the C_{1-6} alkyl being optionally substituted with 1, 2 or 3 R_e;

R_a, R_b, R_c, R_d and R_e are each independently selected from the group consisting of H, F, Cl, Br, I, OH, CN, NH_2, CH_3, , , , , , , ,  and , the CH_3, , , , , , , ,  and  being optionally substituted with 1, 2 or 3 R; and

each R is independently selected from the group consisting of F, Cl, Br, I, OH, CN, NH_2, CH_3, , , , , , , , , , , , , ,  and .

2. The compound, the stereoisomer or the tautomer thereof or the pharmaceutically acceptable salt thereof according to claim 1, wherein R_a, R_b, R_c, R_d and R_e are each independently selected from the group consisting of H, F, Cl, Br, I, OH, CN, NH_2, CH_3, , , , , , , , , , , , , , , , and .

3. The compound, the stereoisomer or the tautomer thereof or the pharmaceutically acceptable salt thereof according to claim 1 or 2, wherein R_1 is selected from the group consisting of H, F, Cl, Br, I, CN, CH_3, , , , cyclopentyl, cyclobutyl, , , NH_2, , and , the CH_3,

, cyclopentyl and cyclobutyl being optionally substituted with 1, 2 or 3 R_d.

4. The compound, the stereoisomer or the tautomer thereof or the pharmaceutically acceptable salt thereof according to claim 1 or 2, wherein R_1 is selected from the group consisting of H, F, Cl, Br, I, CH_3 and .

5. The compound, the stereoisomer or the tautomer thereof or the pharmaceutically acceptable salt thereof according to claim 1 or 2, wherein R_2 is selected from the group consisting of ,  and , the ,  and  being optionally substituted with 1, 2 or 3 R_e.

6. The compound, the stereoisomer or the tautomer thereof or the pharmaceutically acceptable salt thereof according to claim 5, wherein R_2 is .

7. A compound of the formula below, a stereoisomer or a tautomer thereof or a pharmaceutically acceptable salt thereof,



.

8. The compound, the stereoisomer or the tautomer thereof or the pharmaceutically acceptable salt thereof according to claim 7, selected from



.

9. A pharmaceutical composition comprising the compound, the stereoisomer or the tautomer thereof or the pharmaceutically acceptable salt thereof according to any one of claims 1 to 8.

10. Use of the compound, the stereoisomer or the tautomer thereof or the pharmaceutically acceptable salt thereof according to any one of claims 1 to 8 in the manufacture of a pharmaceutical composition for agonizing TLR8.

11. Use of the compound, the stereoisomer or the tautomer thereof or the pharmaceutically acceptable salt thereof according to any one of claims 1 to 8 in the manufacture of a pharmaceutical composition for treating a disease responsive to TLR8 agonism.

12. The use according to claim 11, wherein the disease responsive to TLR8 agonism is viral infection.

13. The use according to claim 12, wherein the viral infection is hepatitis B virus infection.